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SHowever, the present study had some limitations. First,
the CRM-positive and R1 radial margin groups (44 and 8
patients, respectively) were relatively small. This could
have led to underpowering, especially in the R1 group anal-
yses in which a type II error might have been present. Two,
the pathologic evaluation of the specimens is often per-
formed by a single pathologist without secondary verifica-
tion. Third, just as with any retrospective study, selection
bias is a concern. The propensity score match was per-
formed in an attempt to mitigate this sort of bias. Fourth,
it is difficult to establish a specific protocol for pathologic
fixation of specimens that simultaneously involve several
body cavities. Thus, there could be times when the surgeon
performs what they perceive to have been an R0 resection,
but a positive CRM is found because the envelope of sur-
rounding pleura or soft tissue was disrupted.CONCLUSIONS
A close (<1 mm) radial margin in patients undergoing
esophagectomy after neoadjuvant chemoradiotherapy
does not appear to be an independent predictor of survival,
local recurrence, or disease-free survival. An involved ra-
dial margin, however, might be the more clinically relevant
definition. Future studies concerning multimodality therapy
with chemoradiotherapy and surgery should include the
CAP definition of radial margin involvement.References
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DrGail E. Darling (Toronto, Ontario, Canada). I want to thank
Dr Harvin for an excellent presentation and for providing me with
the manuscript well in advance of the meeting.
You have addressed a very important question regarding posi-
tive circumferential radial margins, and, specifically, you have ad-
dressed the problem of two conflicting definitions. Your results
have shown that the Royal College of Pathologists’ definition
has no predictive value in terms of survival, and that is in contrast
to a number of other reports. How do you explain the difference in
your results compared with previous reports using that Royal Col-
lege definition?
Dr Harvin.Well, our data are unique in that all patients in this
analysis underwent neoadjuvant chemoradiotherapy. The other
studies that have looked at this subject have either contained
a very small percentage of patients receiving neoadjuvant chemo-
radiotherapy or none at all. We are in agreement with some other
studies. For example, Deeter, published a report in 2009 that
showed that the definition of a positive radial margin by the Col-
lege of American Pathology definition was a more clinically-rele-
vant definition. We certainly are in agreement with that study.
Compared with some of the other studies that our results contra-
dict, they only used the Royal College of Pathology definition.
They did not differentiate their patients by tumor at the margin ver-
sus tumor at or within. Because we don’t know the incidence or
significance of tumor at the margin in those studies, we could
not compare our results to theirs.
Dr Darling. Do you think that the radiation plays a significant
role in your ability to achieve an R0 resection?
Dr Harvin. There is level 1 data that R0 resections are more
common after neoadjuvant chemoradiotherapy rather than, say,
neoadjuvant chemotherapy or surgery alone. We believe that the
neoadjuvant chemoradiotherapy allows us to have more complete
resections. This was, however, not a randomized study, so we can-
not determine from this study what role radiation may play.
Dr Darling. My other question relates to your surgical ap-
proach. The majority of your patients had transthoracic resections.
Do you think that had an effect on your results?
Dr Harvin. In terms of the data, we did not see any difference
between the types of surgery and involved radial margins, so we
cannot say that the type of surgery affected our results. The num-
bers for some of the different types of operations were small, how-
ever, so it could have been underpowered.
Dr Darling. I’m sorry, I should have made my question more
clear. Do you think that that might explain the difference between
your results and some of the other studies?ery c February 2012
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SDr Harvin. I don’t think we can answer that question from the
data we have collected.
Dr Darling. You excluded patients with positive proximal or
distal resection margins, but it seems there’s only a very small
number of patients in that group. Do you think that if we exclude
patients with positive proximal and distal margins that it’s very
likely that the radial margin will also be negative? Can we use
that as a predictor?
Dr Harvin. Although it’s possible, the number of patients with
positive proximal or distal margins and a positive radial margin
were very few. So, I do not think we can use proximal or distal mar-
gin status as a marker for radial margin status.
Thank you, Dr. Darling, for your questions and for evaluating
the manuscript.
Dr BrendonM. Stiles (New York, NY). Thank you very much. I
enjoyed the talk.
I have two questions I was hoping to ask. One, can you predict
the type of patients who are going to have positive margins? Some
of that is by the type of surgery, but some also by the location of the
tumor, by the histology of the tumor.
Dr Harvin. Can you repeat your question?
Dr Stiles. Are you able to get a sense of which patients are go-
ing to have positive margins going in? Is there a predictor; the type
of surgery, whether they responded to induction therapy, the loca-
tion of the tumor, gastroesophageal junction versus lower
esophagus?
Dr Harvin.We do not have that analysis for the exact patients
we presented today. However, an older multivariate analysis of
similar ypT3 patients found that radiation doses greater than 45
Gy and pathologic lymph node status were independent predictors
of a positive CRM (tumor at or within 1mm of the radial margin).
Dr Stiles.My second question is how the patients responded to
induction therapy. I know that in a lot of the publications from your
institution, the response to neoadjuvant therapy has been a very
powerful predictor of outcome. We have seen similar results.
When we have tried to look at the effect of extended lymphadenec-
tomy in this kind of group of patients, what we have seen is that in
the responders it probably doesn’t matter as much because they
have a great systemic response and they are probably not going
to have as bad an outcome. Conversely, in the nonresponders,
we see that actually more aggressive local resection becomes
more important. Have you looked at the clinical response and
are you able to tell the difference between those two groups of
patients?
DrHofstetter. In a multivariate analysis, both histoviability and
response were included, and it wasn’t an independent predictor. So
we couldn’t predict whowas going to have a positive margin based
on whether they had a response or not, and that’s why, when we did
the original analysis, we included all patients and all comers rather
than focusing on just the ypT3s. The interesting finding in our data
was that when we looked at thewhole group, the CRM-positive pa-
tients actually performed slightly better than the CRM-negative
ones. If you recognize the first Kaplan-Meier curve, wewere above
it—and that was including all patients who were ypT0N0M0 as
well.
In terms of your question about location or histology, thosewere
both included and were not independent predictors, so we couldn’t
exactly delineate which were or which would not be. Now, I don’tThe Journal of Thoracic and Cawant to be the naysayer about the minimally invasive esophagec-
tomy (MIE) procedure, but I will say that perhaps early in our
learning curve, 50% of the patients who had undergone an MIE
procedure had a close margin, although, according to the CAP def-
inition, only 1 of 12 was positive. So this might, again, be early in
our learning curve. It was not statistically significant, but if there
was anything to delineate transthoracic versus transhiatal MIEs,
which at that point we were doing a lot of, we had a fewmore close
margins in that situation.
Dr Thomas W. Rice (Cleveland, Ohio). I have a comment
about your analysis. If you continue to distill your data, eventually
you’re going to select out the worst people, and if you perform
multiple, multiple tests, eventually one is going to be positive by
chance. I have some advice. This was a retrospective study. You
must match patients who don’t have a positive resection margin
with those who don’t have a positive resection margin, because
generally the people with the positive resection margins have the
bigger tumors. And you can’t compare a T1 to a T3. You have
to compare a T3 and a T3, a T3 with a positive resection margin
versus a T3 without. So you must propensity-match it and then
you can tell us. You’ll maximize the use of your data and you’ll
give us some very valuable information. Thank you very much.
Dr. Harvin.Actually, we did do a propensity score match and it
showed no difference. We did not include that because our patients
were so alike in the ypT3 group that we thought it wouldn’t add
much to the analysis.
Dr Rice. It’s much better to include it. It will make it a much
more valuable paper for the reviewers and the editors to see it.
Dr Harvin. Yes. Thank you, sir.
Dr Avi Lebenthal (Boston, Mass). I enjoyed your presentation.
The problem I have with this topic is the pathology; it’s not re-
ally the surgery. What we have learned from the analysis of nodes
in esophageal cancer is that when the Japanese cut them between 5
and 10 times, they get a very different incidence of node positivity
than we do when we cut them once or when in Belgium they cut
them 3 times. So it’s very different in different places. It could
be that the difference between the 1 mm and the positive margin
is a function of also how the pathologist is looking at it. So if
you really want to do this prospectively, I think, as a discipline,
we have to sort of decide what the pathologist has to analyze in
the tissue, because otherwise we’re all collecting different data.
Dr. Harvin. Yes, sir.
DrMark J. Krasna (Towson, Md). I enjoyed your presentation,
Dr. Harvin.
For you and Dr Hofstetter, there are data in rectal cancer that are
very similar to this that I’m sure you’re aware of if you looked at
circumferential radial margins because it’s the only other place we
look at it routinely. The reason I bring it up is, with the new staging
system,Wayne, you’re always talking about what’s the clinical ap-
plication, how are we going to use it in clinical hands. What they
do now in rectal cancer, based on the British data from multidisci-
plinary prospective reviews of MRIs, they predefine a subgroup of
patients who might be likely to have a circumferential radial mar-
gin versus those negative, and this answers what Brendon was get-
ting at. Do either of you have any thoughts about any of our current
diagnostic testing, whether it’s EUS or adding MRI in the esoph-
agus, like rectal, that you might be able to predetermine that group
of patients?rdiovascular Surgery c Volume 143, Number 2 419
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SDrHofstetter.That’s a good question,Mark, and thank you for it.
Our opinion in general, ongoing, is that we should be looking at
a positive circumferential radial margin as the most significant one
and that we need to be including that definition in our randomized
trials. Whether or not it’s at 1 mm or 2 mm, which is what the co-
lorectal surgeons have established, versus at the margin, I think
might be site specific and it might also be treatment-specific. So
we’re trying to establish that CAP is the most relevant criteria
and we’re going to advocate using that going forward. In terms
of what studies would be best for that, I don’t know. I think that
the pathologist makes a big difference, but also the surgery does
too. I know that most of you, after you have done your transtho-
racic or modified en bloc esophagectomy don’t go back and sew
the pleura down to where it was over the tumor, you know, to
say, well, don’t disrupt this when it goes on its way over to pathol-
ogy, and that might also have a significant effect on these close
margins. The positive margins are positive likely because the sur-
geon can’t go any further, meaning this is a T4a or it’s into the
pleura, and everything has been resected, and this is more of
a marker of disease than a marker of surgery.
Dr Krasna. Can EUS or MRI—?
Dr Hofstetter. I don’t know the answer to that. At our institu-
tion we had the guys doing EUS calling it T4a very frequently,
and we did not use that as an indicator to change our therapy or
change our operation, because not infrequently the call of T4420 The Journal of Thoracic and Cardiovascular Surgwas incorrect or it wasn’t borne out from the standpoint of surgery.
Now, whether that’s due to downstaging or not, I don’t have the
data for that.
Dr Scott Swanson (Boston, Mass). I really enjoyed that paper.
In follow-up to what you just said, what do you do with those pa-
tients who have tumor at the margin? If you’re giving them chemo-
radiotherapy, you know they are going to have a high chance of
local recurrence as well as systemic recurrence. What’s your treat-
ment modality? Is there a radiation strategy, pure chemo strategy,
IMRT? What do you do with them?
Dr Hofstetter. We entered into this project as a fact-finding
mission. We didn’t know quite what we were going to find with tu-
mor close to the margin versus at the margin. As you saw, it was
a fairly frequent finding for patients who were having a transmural
viable tumor but didn’t know whether it was at all significant.
I think it’s interesting to note that the patients who have disease
at the margin didn’t do as well, but their local recurrences weren’t
any higher, and I think it’s a marker for bad disease. Unfortunately,
as you know, at this point there are several indicators for patients
who are going to do poorly, none of which we know completely
how to treat, but excess lymph node involvement, lymphovascular
invasion, and I think disease at the margin is one of those other
poor indicators, but of systemic disease, not necessarily of locore-
gional failure. So maybe that’s something that we need to look at
into the future.ery c February 2012
